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Abstract 
Purpose: To describe the intraoperative multicatheter implantation technique for accelerated partial breast irradia-
tion (APBI) delivered with high-dose-rate brachytherapy (HDR-BT). Secondarily, to evaluate outcomes and toxicity in 
a series of 83 patients treated with this technique at our institution. 
Material and methods: Retrospective analysis of a series of patients treated with HDR-BT APBI after intraopera-
tive multicatheter interstitial implant between November 2006 and June 2017 at our institution. We assessed cosmesis, 
toxicity, overall survival (OS), and disease-free survival (DFS). 
Results: Eighty-three patients were included: 59 patients (71.1%) with primary early-stage breast cancer and 
24 (28.9%) with locally recurrent breast cancer. Tumorectomy was performed in all cases, with intraoperative tumor 
margin assessment and sentinel node biopsy. Median age was 82 years (range, 44-92). The total prescribed dose was 
32 Gy (8 treatment fractions) in 60 patients (72.3%), and 34 Gy (10 fractions) in 23 patients (27.7%). Median follow-up 
was 40 months (range, 1-136 months). Three-year OS and DFS in the recurrent and primary cancer groups were 
87% vs. 89%, and 96 % vs. 97.8%, respectively. Five patients died from non-cancer related causes. No local relapses 
were observed. Rates of acute and late toxicity were low in both groups. The cosmesis was good or excellent in most of 
patients treated for primary disease; in patients who underwent salvage brachytherapy for local recurrence, cosmesis 
was good in 49 patients and fair in 6. 
Conclusions: This technique, although time-consuming, achieves good local disease control with a satisfactory tox-
icity profile in both early-stage and local recurrent breast cancer patients. It may be especially suitable for frail patients. 
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Purpose 
Accelerated partial breast irradiation (APBI) is usually 
performed as a post-lumpectomy radiotherapy technique 
for women with early-stage breast cancer to deliver treat-
ment exclusively to the tumor bed. Historically, adjuvant 
whole-breast irradiation (WBI) after lumpectomy has 
been considered the standard therapeutic approach, with 
rates of overall survival and locoregional control compa-
rable to mastectomy alone [1]. However, recent data pub-
lished by Strnad et al. clearly determine the non-inferior-
ity of the partial irradiation approach in the treatment of 
early breast cancer [2]. The rationale for partial breast irra-
diation is supported by data from three randomized trials 
demonstrating that most recurrences following lumpecto-
my alone, occur adjacent to the lumpectomy cavity [3,4,5] 
and therefore, WBI might be unnecessary. For this reason, 
interest in APBI, which targets only the area surrounding 
the tumor site, has increased in recent years [6,7]. 
One of the main benefits of APBI is that it reduces the 
total treatment time from 3-6 weeks to less than a week, 
which improves patients’ satisfaction and overall quality 
of life, especially for those patients who live far from radi-
ation centers. APBI can also lower the radiation doses to 
the healthy surrounding organs and tissues, thus reduc-
ing toxicity and improving cosmesis. In addition, cost- 
effectiveness ratio for APBI is lower than for WBI [8]. 
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Several APBI techniques have been developed as al-
ternatives to the more conventional post-operative ap-
proaches [9,10,11], including single-entry intracavitary 
devices, multi-lumen balloons, and external beam radi-
ation therapy with low energy X-ray. Nevertheless, the 
most widely used technique with the longest history 
and follow-up is interstitial multicatheter brachytherapy 
[12,13]. In the conventional approach to interstitial mul-
ticatheter brachytherapy, the percutaneous catheters are 
inserted 2-3 weeks after breast surgery, when the resected 
tissue has already been analyzed and the complete patho-
logical report is available. At our institution, we have pro-
posed an alternative approach to all patients who live far 
from the treatment center or who are frail: implantation 
of the catheter during tumor resection to perform peri-
operative APBI. The objective of this approach is to avoid 
the need for a second surgical procedure. This approach 
is also used to treat recurrent disease as a second conser-
vative treatment. 
Intraoperative multicatheter implantation delivered 
with high-dose-rate (HDR) brachytherapy (MC-HDR) 
provides excellent coverage to the entire tumor bed. In 
addition, compared to post-operative brachytherapy, the 
intraoperative approach allows for direct visualization of 
the tumor bed and, consequently, more accurate place-
ment of the catheters. At our institution, we perform com-
puted tomography (CT) scan 48-72 hours post-operative 
to minimize the risk of movement or displacement. Pub-
lished reports on this intraoperative approach are scant, 
despite the important advantages over post-operative 
catheter implantation [14]. However, Gurram et al. found 
no difference in implant quality between intraoperative 
and post-operative catheter implants, but they recom-
mended the intraoperative technique due to the advan-
tage of direct visualization of the tumor cavity [15]. 
In this context, the main objectives of the present 
study were: 1. To describe in detail the intraoperative 
technique of interstitial multicatheter implantation; and 
2. To evaluate the advantages of this approach compared 
to conventional post-operative catheter insertion and to 
competing IORT techniques. In addition, we report out-
comes and toxicity in a series of 83 patients treated with 
this technique at our institution. 
Material and methods 
Between November 2006 and June 2017, 83 patients 
(59 patients with early-stage primary breast cancer and 
24 with recurrent breast cancer) were treated with intra-
operative MC-HDR brachytherapy for APBI at the Cata-
lan Institute of Oncology, Barcelona, Spain. We retrospec-
tively analyzed the outcomes of these patients. The study 
was conducted in accordance with our institutional pro-
tocols. Written informed consent was obtained from each 
patient before starting the procedure. 
All patients underwent tumorectomy with a resection 
margin that included sufficient normal breast tissue to 
ensure tumor-free margins. Sentinel node biopsy (SNB) 
was performed in all cases, except for patients with re-
current disease who had undergone axillary lymph node 
dissection for the primary tumor. 
Candidates for APBI were those who met the crite-
ria for APBI [16,17,18], and those patients who refused 
mastectomy after developing a local recurrence following 
conservative surgery and adjuvant WBI and thus, were 
receiving a second treatment. Consequently, eligibili-
ty criteria for intraoperative MC-HDR were as follows: 
unicentric, unifocal tumor with negative margins and 
negative SNB; breast anatomy suitable for multicatheter 
implantation; locally-recurrent disease or frail/elder-
ly patients in whom the decision to perform APBI with 
MC-HDR was made prior to surgery to avoid the risks 
associated with a second procedure (due to frailty). 
Follow-up, consisting of complete clinical examina-
tions, was performed according to the following sched-
ule: initially, at 2 months post-treatment, then every 
6 months for the first two years, and annually thereafter. 
All the patients underwent an annual mammography. 
Implant technique and treatment delivery 
The tumorectomy was performed under general anes-
thesia. Six metallic clips were inserted into the tumor bed 
limits as described by Major et al. [19]. Next, the resected 
tumor and SNB (if performed) were sent to the laboratory 
for assessment. After intraoperative pathological confir-
mation (achieved within 15 minutes after tumor resection 
in most cases) of the negative sentinel lymph node and 
negative tumor margins, metallic needles were manual-
ly inserted around the open cavity, using a plastic guide 
template with needle holes to achieve geometric distri-
bution. Previously, all entry and exit points were marked 
on the skin surface to plan the needle distribution. 
The needles were spaced to form equilateral triangles of 
1.6 cm and inserted in two to four planes, beginning in 
the inferior plane to ensure sufficient radiation coverage 
to the deep tumor cavity under direct visualization; ap-
plicators in the superior planes were implanted only after 
closure of the surgical cavity. The needles were then re-
placed by plastic tubes and attached with buttons at both 
ends (Figures 1 and 2). The number of applicators and 
tubes used varied according to the tumor cavity size and 
breast anatomy. 
A computed tomography (CT) scan with 2 mm slice 
thickness was performed in the Radiation Oncology De-
partment after the definitive pathologic findings from 
the surgical specimen were available (usually within 3 to 
5 days after surgery). The Oncentra system (Elekta Com-
pany, Veenendaal, The Netherlands) was used for treat-
ment planning. The planning target volume (PTV) was 
defined according to the surgical margins to assure a total 
margin of 20 mm around the tumor boundaries. In cases 
in which the PTV overlapped the skin and/or chest wall, 
a margin of 5 mm was cropped out of these structures [20]. 
Patients were treated with HDR-BT with a 192Ir 
source delivered in 2-3 fractions per day, with a mini-
mum of 6 hours separation between fractions. In all cases, 
brachytherapy started within days after surgery. Patients 
were offered one of two options: either to remain hospital-
ized in the Brachytherapy Unit during the entire course of 
treatment, or to return to the center twice a day to receive 
treatment. 
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A modified Paris system was used for dosimetric pur-
poses [21]. The treatment planning parameters were es-
tablished as follows: at least 90% of the defined PTV was 
to receive 100% of the prescribed dose (coverage ratio 
≥ 0.9); maximum dose to the skin: ≤ 70% of the prescribed 
dose; D90 > 100%, V150 < 50%, with a dose non-compliance 
ratio (DNR) < 0.35 (which was achieved in 86% of cases). 
All patients who underwent MC-HDR from Novem-
ber 2006 through September 2012, received 10 fractions 
of 3.4 Gy in accordance with the technique described by 
Vicini et al. [22]. However, due to the participation of 
our center in the GEC-ESTRO randomized trial [2], the 
treatment scheme was changed in October 2012 to 8 frac-
tions of 4 Gy each (the same scheme recommended by the 
GEC-ESTRO randomized phase III trial). Therefore, the 
fractionation schedule varied slightly among the study 
sample. Nevertheless, the equivalent total dose in 2 frac-
tions (EQD2), with a tumor α/β ratio value of 4, was sim-
ilar in both schemes (41.93 Gy and 42.67 Gy, respective-
ly), with a biological effective dose (BED) of 62.9 Gy and 
64 Gy, respectively. 
In the present report, we describe not only the techni-
cal data for the procedure, but also treatment outcomes in 
terms of overall survival (OS), disease-free survival (DFS), 
local control, cosmesis, and the toxicity profile for all pa-
tients (both primary breast cancer and local recurrence). 
Results 
Eighty-four patients underwent intraoperative inter-
stitial multicatheter implant followed by HDR brachy-
therapy within 2-3 days after implantation. In one case, 
the intraoperative biopsy revealed a positive SNB and 
consequently, definitive intraoperative brachythera-
py was abandoned; instead, the intraoperative implant 
was converted to a boost to the tumor bed (3 fractions of 
Fig. 1. A) Needle application ensuring deep tumor bed coverage. B) Needles inserted in the inferior plane and sutured skin. 
C) Needle implantation in the middle and superior planes with the help of plastic template and metallic bridge. D) Needles 





Fig. 2. Needle substitution by plastic tubes in a rescue im-
plant during oncoplastic surgery
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5 Gy), and the patient received conventional post-oper-
ative WBI 2-3 weeks after surgery. That patient was ex-
cluded from the final analysis. Therefore, our retrospec-
tive analysis included the remaining 83 patients. 
Median follow-up was 40 months (range, 1-136). Me-
dian age was 82 years (range, 44-92) and 71.1 % of patients 
(59/83 patients) were ≥ 70 years. Relevant demographic 
and tumor characteristics are provided in Table 1. 
Fifty-nine patients (71.1%) had a diagnosis of primary 
breast cancer, and 24 (28.9%) had a locally recurrent dis-
ease after previous treatment with WBI to the same breast. 
Most patients (65/83 patients, 78.3%) had infiltrat-
ing ductal carcinoma (Table 1). Of the 59 patients with 
primary breast cancer, 28 were classified as stage I, 25 as 
stage II, and 6 with stage Tis. 40.9% of patients had 
a grade 2 tumor, while 64.4% had luminal A disease. Tu-
mor margins were ≥ 1 mm in all but one patient, who had 
a microscopically positive chest wall margin, considered 
unsuitable for margin expansion. We inserted a medi-
an of 17 tubes. In almost all cases (73/83 patients, 88%), 
3 catheter planes were used. Sixty patients (72.3%) were 
treated according to the revised GEC-ESTRO treatment 
schedule (32 Gy in 8 treatment fractions), while 23 pa-
tients (27.7%) were treated with the original schedule 
(34 Gy in 10 fractions). 
The mean V100 was 154 cm3, with a median of 161.25 cm3 
(range, 54-295.4 cm3). Mean V150 was 46 cm3 and median 
V150 was 49 cm3 (range, 23.5-94.6 cm3). Treatment char-
acteristics and parameters of the dosimetric analysis are 
provided in Table 2. 
Disease control 
The three-year OS in the whole sample (both primary 
cancer and local recurrence groups) was 95%. Notably, 
none of the five deaths were attributed to breast cancer, 
and no evidence of relapse was observed in any of those 
cases. The 3-year DFS rate for the whole sample was 97%, 
and no local failures were recorded. 
The 3-year OS and DFS rates in the recurrent and pri-
mary cancer groups, respectively, were as follows: OS – 
87% vs. 89%, and DFS – 96% vs. 97.8%. 
Among the 24 patients treated for local recurrence, 
one was diagnosed with contralateral breast cancer four 
years after treatment, two (8.3%) experienced a second 
relapse (not local), and one presented positive region-
al lymph nodes and bone metastasis on a PET-CT scan 
performed one month after brachytherapy treatment, 
suggesting that the patient had been understaged at the 
time of surgery. The other recurrence occurred in a pa-
tient who presented with bone metastases 10.5 years after 
APBI (21 years after primary breast cancer diagnosis). 
Toxicity and cosmetic outcomes 
Of the 59 patients treated for primary breast cancer, 
acute toxicity (infectious mastitis) was observed in one 
patient (1.6%). Based on that case, we now routinely 
administer antibiotic therapy for all intraoperative ap-
proaches. Of the 24 patients treated for local recurrence, 
eight developed acute toxicity. Of these, 7 (31.9%) were 
infectious mastitis and 1 (4.3%) hematoma. 
Six patients did not reach the minimum follow-up of 
6 months to evaluate late toxicity; therefore, late toxicity 
was evaluated only in 77 patients (55 patients in the pri-
mary breast cancer group and 22 patients in the recur-
rence group). In the primary breast cancer group (n = 55), 
late toxicities were as follows: fibrosis ≥ G3 in 3 patients 
(5.6%), mastitis in 3 cases (5.5%), and hypochromic skin 













Local relapse 24 (28.9)
N stage
pN0 (sn) 81 (97.6)
pN1mi (sn) 2 (2.4)
Histological subtype
Ductal invasive 65 (78.4)
Carcinoma in situ 7 (8.4)
Mucinous invasive 5 (6)
Papilar invasive 4 (4.8)
Lobular invasive 1 (1.2)
Mixed infiltrating ductal-lobular 1 (1.2)
Intrinsic subtype
Luminal A 38 (45.7)
Luminal B 15 (18.2)
ErB2 overexpression 4 (4.8)
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spots at the catheter entrance and exit points in 8 patients 
(14.8%). Late toxicities in the local recurrence group 
(n = 22) were as follows: fibrosis ≥ G3 in 15 patients (68%), 
mastitis in 6 cases (27.3%), and hypochromic skin spots at 
the catheter entrance and exit points in 8 patients (36.4%). 
Tables 3 and 4 provide the acute and late toxicity profile 
for both groups. 
Cosmetic outcomes, determined according to on 
the 4-point Harvard breast cosmesis scale [23] were as 
follows: in the primary breast cancer group: excellent 
(6 patients, 11.1%), good (49 patients, 63%), fair (1 patient, 
1.8%), and poor (0 patients); in 2 cases (4.9%), no cosmetic 
ratings were available. Cosmetic outcomes in the local re-
currence group were: good (49 patients, 63%), fair (6 pa-
tients, 27.3%), and poor (7 patients, 32%); in 4 cases (7%), 
no cosmetic ratings were available. In the local recurrence 
group, no data were available regarding the cosmetic out-
comes after primary treatment. 
Discussion 
In recent years, the body of evidence from random-
ized clinical trials supporting the use of APBI versus WBI 
has increased substantially. Consequently, APBI is cur-
rently an accepted alternative to WBI in selected patients 
[7,18], because it offers comparable survival rates, better 
cosmesis, and a less burdensome treatment [2,24,25,26]. 
In addition, recent analyses by Shah and Lanni have 
demonstrated that brachytherapy-based APBI reduces 
overall financial cost of treatment [27,28]. 
The present study provides a detailed description of 
the intraoperative approach to interstitial multicatheter 
implantation. We also provide outcomes and toxicity in 
a series of 83 patients treated with this approach, with re-
sults that are comparable to WBI in terms of low toxicity 
and excellent survival rates. Although five patient deaths 
occurred during the follow-up, the causes (i.e. for cardio-
vascular or pulmonary diseases) were unrelated to breast 
cancer or treatment. Notably, no cases of local relapse 
were observed. These findings support the effectiveness 
of intraoperative MC-HDR brachytherapy for APBI in the 
treatment of both locally recurrent and early-stage breast 
cancer. 
The intraoperative implantation of multicatheters of-
fers many advantages. First, it avoids the need for a sec-
Table 2. Treatment characteristics and dosimetric 
analysis 
Doses and fractionation 34 Gy/10 Fr 
32 Gy/8 Fr 
n = 23 (27.7%)
n = 60 (72.3%)
No of catheter plans Median 3
Range 1-4
No of catheters Median 17
Range 9-18
















PTV volume Mean 130 cm3 
Range 73-232.5 cm3 
V100, V150 – volume of the anatomic volume receiving 100%, 150% of the pre-
scribed dose, PTV – planning target volume 
Table 3. Toxicity profile: patients treated for 
primary breast tumor
Percentage of patients 
Acute toxicity (59 patients)
Infectious mastitis 1.6 (n = 1)
Hematoma 0 (n = 0)
Late toxicity (55 patients)
Fibrosis G0-G2 94.4 (n = 52)
Fibrosis G3 5.6 (n = 3) 
Fibrosis G4 0 (n = 0) 
Mastitis 5.5 (n = 3) 
Hypochromic skin spots 14.8 (n = 8) 
Skin hyperpigmentation 7.4 (n = 4) 
Telangiectasia 1.9 (n = 1) 
Fat necrosis 0 (n = 0) 
Table 4. Toxicity profile: patients treated for 
breast local recurrence 
Percentage of patients 
Acute toxicity (23 patients)
Infectious mastitis 30.4 (n = 7) 
Hematoma 4.3 (n = 1) 
Late toxicity (22 patients)
Fibrosis G0-G2 31.9 (n = 7) 
Fibrosis G3 50 (n = 11) 
Fibrosis G4 18.1 (n = 4) 
Mastitis 27.3 (n = 6) 
Hypochromic skin spots 36.4 (n = 8) 
Skin hyperpigmentation 13.6 (n = 3) 
Telangiectasia 31.8 (n = 7) 
Fat necrosis 4.5 (n = 1) 
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ond surgical intervention and the risks related. In addi-
tion, this procedure allows for direct visualization both 
operating bed and the implant site and, consequently, 
a more accurate placement. In addition, of the various 
APBI techniques, multicatheter interstitial BT has the 
longest track record, and two randomized phases 3 trials 
have demonstrated that it is comparable to WBI [2,29]. 
Another advantage of APBI is reduced treatment time 
versus WBI, which requires from 3 to 6 weeks of daily 
sessions, being inconvenient particularly for the elderly 
and for patients with mobility problems, or those who 
live far from the radiation therapy facility [30]. By con-
trast, not only does APBI reduce treatment time, but it 
guarantees excellent coverage of the tumor bed and de-
creases radiation doses to nearby organs and structures 
such as the lungs, heart, and ribs [31]. 
Interest in the use of IORT for APBI has increased in 
the last 10-15 years, with the emergence of techniques such 
as MammoSite balloon brachytherapy, Intrabeam IORT, 
and electron IORT [10]. Although these techniques have 
been embraced by many clinicians, their appearance has 
also resulted in important controversies due to the lack of 
a definitive pathological diagnosis before irradiation, and 
to the impossibility of ensuring complete coverage of the 
tumor bed and margins [32,33]. In this sense, convention-
al (i.e. post-operative) multicatheter brachytherapy offers 
an excellent alternative to both WBI and IORT, because it 
does not suffer from the aforementioned disadvantages. 
Recently, Strnad et al. [2] reported results from the 
GEC-ESTRO phase 3 APBI trial that assessed APBI ad-
ministered via exclusive multicatheter brachythera-
py. The results demonstrated that this technique after 
breast-conserving surgery was as effective as adjuvant 
WBI in carefully selected, early-stage breast cancer pa-
tients, and that multicatheter brachytherapy for APBI 
was not inferior to WBI – in contrast to the results report-
ed in the ELIOT and TARGIT trials, both of which failed 
to prove the non-inferiority of IORT to WBI [10,34]. 
The insertion of the catheters intraoperatively rather 
than post-operatively is what differentiates the technique 
described in the present article from the technique used 
in the GEC-ESTRO study. Theoretically, intraoperative 
implantation should provide a small advantage in terms 
of local control and toxicity due to better accuracy of the 
catheter placement offered by direct visualization of the 
operating bed. Moreover, as with conventional post-op-
erative multicatheter brachytherapy, intraoperative 
MC-HDR avoids the drawbacks of other IORT tech-
niques, which use instruments with a spherical applicator 
that do not conform the surgical cavity, thus leading to in-
complete coverage. By contrast, intraoperative MC-HDR 
allows a precise implantation and irradiation around the 
tumor bed at 1-1.5 cm, providing excellent coverage of 
the entire tumor bed and margins. As our results show, 
at least 90% of the defined PTV received 100% of the pre-
scribed dose (coverage index ≥ 0.9). PTV underdosing 
areas were only accepted to meet dose constraints of the 
skin and chest wall. 
Another benefit of intraoperative MC-HDR is that 
treatment planning and radiotherapy delivery are per-
formed only few days after surgery when the final patho-
logical diagnosis becomes available, an approach that 
bridges the gap between other IORT techniques, in which 
the patient is irradiated before definitive pathological as-
sessment. 
Notwithstanding the long history and proven efficacy 
of interstitial multicatheter brachytherapy in APBI, only 
a few reports have described the intraoperative MC-HDR 
technique [14,35]. Sato et al. [14] provided in-depth de-
scription of this approach in a study conducted to assess 
the feasibility and safety of catheter insertion during tu-
morectomy. In that study, the authors report good tumor 
control with low toxicity rates in 157 patients who under-
went intraoperative multicatheter implantation followed 
by HDR brachytherapy. 
In the setting of local recurrent breast cancer, multi-
catheter interstitial brachytherapy after salvage tumorec-
tomy has been shown to achieve good disease control. 
A multicentric retrospective study conducted by Han-
noun-Levi as a part of the GEC-ESTRO breast cancer 
group [35], assessed 217 patients with locally recurrent 
breast cancer, many of whom (precise data not provided) 
underwent intraoperative catheter implantation. In that 
study, which included patients with unifocal tumors (any 
histological type) ≤ 35 mm in size, a maximum of 3 posi-
tive regional lymph nodes and no distant metastasis; five-
year OS and local recurrence rates were 88.7% and 5.6%, 
respectively. Breast cosmesis was considered excellent or 
good in 85% of cases. 
In our series, data on cosmetic outcomes and fibrosis 
were slightly worse than those reported in other studies. 
These results can be explained by the fact that the patients 
who showed the greatest toxicity were those treated for 
recurrence, who had already undergone surgery and 
adjuvant WBI, and thus had a greater risk of develop-
ing toxicity. By contrast, cosmesis in the patients treated 
for primary disease was either good or excellent in most 
cases. Although cosmesis was considered satisfactory in 
most of the patients who underwent APBI due to locally 
recurrent disease, our results suggest that patients with 
locally recurrent disease should be informed that cos-
metic outcomes may be less than optimal. Nevertheless, 
patients (and clinicians) may consider this to be an ac-
ceptable trade-off given the good survival rates achieved 
with this treatment approach, especially given that the 
only alternative is mastectomy (with or without recon-
structive surgery). 
Importantly, we observed no local recurrences in our 
series, a finding that underscores the excellent tumor con-
trol achieved with this technique. However, given the rel-
atively short follow-up in our series (median, 40 months), 
some recurrences may occur in the future. Indeed, Aristei 
et al. [36] recently reported long-term results of intra- and 
peri-operative interstitial multicatheter HDR implants for 
APBI. In that study, they described that although the rate 
for local relapses was quite low (1.8%) at 5 years, it went 
up to 6.6% at 10 years. That is one of the reasons why pa-
tients must be followed up for at least 10 years – not only 
to rule out local relapse, but also to evaluate accurately 
the incidence of secondary effects. 
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Toxicity rates in our sample were low in both groups. 
Although several cases of acute and chronic mastitis were 
observed, these were successfully managed with sup-
portive therapy without the need of additional surgery. 
One option to further reduce the complication rate could 
be to decrease the V150. However, it is important to keep 
in mind that because APBI is only a partial breast treat-
ment, the PTV should be well-covered. In addition, it is 
necessary to consider interobserver variations in the CTV 
definition, as demonstrated by Upreti et al. [37], especially 
when the cavity visualization index is low. 
Study limitations 
The main limitations of this study were its retro-
spective design, small sample size, and relatively short 
follow-up. Furthermore, we included patients with pri-
mary and recurrent tumors, which could be considered 
two different biologic diseases. This is why survival and 
toxicity data were analyzed separately in two groups. 
Another limitation is that the treatment scheme was not 
homogenous among all patients because we modified 
our treatment schedule during the study period, with 
just over half receiving 32 Gy (8 fractions) versus 34 Gy 
(10 fractions). Finally, it is also important to emphasize the 
complexity of this technique, which requires a high level of 
operator experience. For this reason, we believe this tech-
nique should only be performed in reference centers. 
Conclusions 
The present study provides a comprehensive descrip-
tion of the indications for intraoperative insertion of cath-
eters for APBI. APBI using intraoperative interstitial mul-
ticatheter HDR, allows good tumor control in carefully 
selected patients; disease control rates are comparable to 
WBI, with low toxicity profile. Survival and local control 
rates are also good even in patients who undergoing sal-
vage tumorectomy for local recurrence. However, in this 
patient subgroup, cosmesis may not be absolutely satis-
factory, although the only alternative is mastectomy. 
Among the various techniques for intraoperative 
APBI, we believe that interstitial multicatheter implanta-
tion merits more attention given its excellent theoretical 
and practical advantages over competing approaches. 
Intraoperative catheter insertion has the advantage of 
a greater accuracy in target implantation, a shortened 
interval between surgery and radiotherapy, and the 
avoidance of a second invasive procedure. This treatment 
modality may be especially suitable for elderly or frail 
patients with early-stage disease and for patients with lo-
cally recurrent breast cancer. 
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